Invitrogen will manufacture ViaCell’s ViaCyte media, an investigational product for use during assisted reproductive technology. ViaCyte is a pivotal clinical trial to evaluate the cryopreservation and thawing of human oocytes.
ViaCell plans to commence the open-label evaluation of safety and efficacy of its freeze and thaw media for fertility preservation in the first quarter of 2007. The trial will seek to enroll approximately 300 healthy women, between 21 and 35 years, who are currently seeking fertility treatment. The primary efficacy endpoint is 50 live births.
ViaCell's proprietary technology to cryopreserve and thaw human oocytes uses a choline chloride-based media designed to protect the cells from damage during the freezing process.